Jungryun Kim

Light-based phototherapy has been developed for cancer treatment owing to its non-invasiveness and spatiotemporal control. Despite the unique merits of phototherapy, one critical disadvantage of light is its limited penetration depth, which restricts its application in cancer treatment. Although many researchers have developed various strategies to deliver light into deep-seated tumors with two-photon and near-infrared light irradiation, phototherapy encounters the peculiar limitations of light.

Fluorescence imaging in the second near-infrared window (NIR-II) is crucial for accurate tumor diagnosis, offering superior resolution and penetration capabilities. Current NIR-II probes are limited by either being "always on" or responding to one stimulus, leading to low signal-to-noise ratios and potential false positives. We introduced a dual-lock-controlled probe, HN-PBA, activated by both H₂O₂ and tumor acidic environment. This dual response ensures bright fluorescence

Breast cancer has now overtaken lung cancer as the "world's leading cancer," yet detecting and implementing effective therapies remains a significant challenge. Substantial advances have been made in photothermal therapy (PTT), where photosensitizers use photonic energy to induce localized hyperthermia for cancer eradication. This pioneering approach is gaining traction in clinical settings. However, traditional PTT faces inherent limitations, including the risk of damage to neighboring healthy

Abstract Fingerprints are one of the distinguishing characteristics of an individual, remaining unaltered throughout one's lifetime. It should be noted that fingerprints are significant and reliable evidence in various cases, such as criminal investigations, medical diagnosis, and public security. Thus, it is necessary to develop efficient techniques for fingerprints detection. Fortunately, the fluorescence emission of aggregation‐induced emission (AIE) materials would increase instead of quench

Tumor heterogeneity and complex morphologies pose significant challenges to achieving efficient therapeutic outcomes. However, the recent advent of remote-controlled transformable nanostructures has introduced a novel approach to cancer therapy, enabling precise size, shape, and phase changes in nanoparticles in response to external stimuli, such as light, ultrasound, and magnetic fields. These materials offer noninvasive strategies to effectively navigate the dynamic and complex morphologies of

Monodisperse oligomers, positioned as intermediates between polymers and small molecules, retain certain reactivities of small molecules while simultaneously displaying the initial aggregation characteristics of the polymers. This distinctive structure bestows on them with significant potential for a wide range of applications. In this study, a series of carbolong osmium oligomers (<b>Os1</b>-<b>Os4</b>) and corresponding polymer were evaluated as photocatalysts. It was discovered that their mol

Despite the apparent copious fluorescent probes targeting mitochondria, the development of low cytotoxic probes is still needed for improving validation of mitochondrial function assessment. Herein, we report a novel cyanine-based NIR fluorescent probe, T2, which selectively targets mitochondria with significantly low toxicity by modulating the intracellular redox status. Additionally, T2 inhibits oxidative stress-induced cell death in cortical neurons. This study provides new insight into devel

Abstract Fluorescence imaging in the second near‐infrared window (NIR‐II) is crucial for accurate tumor diagnosis, offering superior resolution and penetration capabilities. Current NIR‐II probes are limited by either being “always on” or responding to one stimulus, leading to low signal‐to‐noise ratios and potential false positives. We introduced a dual‐lock‐controlled probe, HN‐PBA , activated by both H 2 O 2 and tumor acidic environment. This dual response ensures bright fluorescence at tumor

Residual tumor cells that persist after chemotherapy, even in minimal quantities, often exhibit drug resistance and increased invasiveness, potentially leading to tumor metastasis and recurrence. This study introduces a novel reactive oxygen species (ROS)-responsive prodrug, <b>Dex-Dox</b>, designed to overcome multidrug resistance (MDR) in tumor cells. The prodrug is composed of the anti-inflammatory glucocorticoid dexamethasone (Dex) conjugated with doxorubicin (Dox), a widely used antitumor a